ReviewAbdominal radiology (New York)2026
Percutaneous sclerotherapy for simple hepatic cysts: a descriptive systematic review and proportional meta-analysis of single-arm studies.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous aspiration and sclerotherapy is a widely used treatment for symptomatic simple hepatic cysts, but the optimal sclerosing agent is unsettled and the literature consists almost entirely of single-arm studies, which cannot support valid between-agent comparison. We performed a descriptive systematic review and proportional meta-analysis restricted strictly to simple hepatic cysts (excluding polycystic liver disease), pooling outcomes within each agent rather than comparing agents. PubMed, Embase, and Cochrane CENTRAL were searched (1,237 records), yielding 25 included studies. Proportional outcomes were pooled with random-effects models on the logit scale (DerSimonian-Laird), with restricted maximum likelihood/Hartung-Knapp and continuity-correction-free (logistic-normal) sensitivity analyses. Prediction intervals and I² are reported, and subgroups of fewer than three studies are described rather than pooled. Symptomatic relief was high and consistent for the two adequately powered agents (ethanol 88.2% [95% CI 82.3-92.3; I²=36%; k = 9]; minocycline 90.3% [77.6-96.2; I²=0%; k = 5]) and similarly high in the two polidocanol/lauromacrogol series (88-100%). Complete radiographic obliteration was not summarizable (ethanol 53.7%, I²=95%, prediction interval 1-99%; polidocanol/lauromacrogol and minocycline each rested on two studies spanning roughly 23-94%). Minor complications differed numerically (polidocanol/lauromacrogol 7.9%, ethanol 19.8%, minocycline 24.1%) but with wide, overlapping intervals. Major procedure-related events were rare but did occur, including one ethanol intoxication with respiratory failure, one hepatic abscess, and one suspected chemical peritonitis. Recurrence, reported over widely varying follow-up, was low but is time-dependent and is presented descriptively rather than as a durability ranking. Symptom relief, not obliteration, is the reproducible and decision-relevant outcome. Agent differences in tolerability and durability are numerical and unconfirmed, so agent selection can reasonably be individualized by operator experience and patient priorities pending randomized trials.
Indexed as
Identifiers
42836988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.